<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007264</url>
  </required_header>
  <id_info>
    <org_study_id>NBS 14.200-CAP1</org_study_id>
    <secondary_id>NL52211.094.16</secondary_id>
    <nct_id>NCT03007264</nct_id>
  </id_info>
  <brief_title>Cold Plasma for Wound Treatment, Safety Study</brief_title>
  <official_title>Safety Assessment of Cold Gas Plasma on Intact Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Dutch Burn Centres</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eindhoven University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Dutch Burn Centres</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the application of cold atmospheric plasma (CAP) will be tested on intact skin
      of volunteers. To test safety, several skin parameters will be monitored, the antimicrobial
      effect will be investigated as well. The investigators expect this treatment to have a good
      antimicrobial effect with acceptable, transient skin sensations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control of infection and bacterial colonisation constitutes a continuing challenge in
      patients with burns. Prevention of microbial contamination and infection is vital for burn
      wound care as bacterial presence can result in excessive inflammatory reactions, delayed
      re-epithelialisation, impaired matrix remodelling and bacteraemia. A novel method to decrease
      the likelihood of infection and to help cure wounds is cold atmospheric plasma (CAP). CAP has
      been shown in vitro to kill a wide range of pathogenic bacteria.

      This safety study aims to demonstrate the safety, efficacy and efficiency of CAP for burn
      wound treatment. Intact skin of volunteers will be CAP treated. Local skin reaction (blister
      formation, pain, itching), erythema, local skin temperature, trans epidermal water loss
      (TEWL) and reduction of the bacterial load wil be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>before to 30 minutes after treatment</time_frame>
    <description>by using a visual analogue thermometer (VAT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local skin reaction</measure>
    <time_frame>directly to 30 minutes after treatment</time_frame>
    <description>blister formation, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local skin temperature</measure>
    <time_frame>before to 30 minutes after treatment</time_frame>
    <description>thermographic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colour/pigmentation</measure>
    <time_frame>before to 30 minutes after treatment</time_frame>
    <description>erythema, redness of the skin, by using a Dermaspectrometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trans epidermal water loss</measure>
    <time_frame>before to 30 minutes after treatment</time_frame>
    <description>barrier function of the skin by using TEWAmeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of the bacterial load</measure>
    <time_frame>directly to 5 minutes after treatment</time_frame>
    <description>quantified with scrub wash method</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Intact Skin</condition>
  <condition>Contaminant Given to Patient</condition>
  <arm_group>
    <arm_group_label>CAP treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volar arm will be treated with cold atmospheric plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAP on bacteria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volar arm with bacteria will be treated with cold atmospheric plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no CAP on bacteria</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cold Atmospheric Plasma</intervention_name>
    <description>CAP will be applied on one volar arm of volunteers for a total of 2 minutes.</description>
    <arm_group_label>CAP treated</arm_group_label>
    <arm_group_label>CAP on bacteria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to comply with the research protocol

          -  No language barrier

        Exclusion Criteria:

          -  Atopic dermatitis or other skin disease

          -  Implanted electrical medical devices such cardiac pacemakers

          -  Pregnant or lactating women

          -  Patients with infected wounds.

          -  Life-threatening cardiac conductivity abnormality

          -  Active malignancy

          -  Women of childbearing age not using contraceptive measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Middelkoop, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Red Cross Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bouke Boekema, PhD</last_name>
    <phone>+31 251 27 55 03</phone>
    <email>bboekema@burns.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marlies kobesen</last_name>
    <phone>+31 251 27 55 00</phone>
    <email>mkobesen@burns.nl</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Kisch T, Schleusser S, Helmke A, Mauss KL, Wenzel ET, Hasemann B, Mailaender P, Kraemer R. The repetitive use of non-thermal dielectric barrier discharge plasma boosts cutaneous microcirculatory effects. Microvasc Res. 2016 Jul;106:8-13. doi: 10.1016/j.mvr.2016.02.008. Epub 2016 Mar 2.</citation>
    <PMID>26944583</PMID>
  </results_reference>
  <results_reference>
    <citation>Brehmer F, Haenssle HA, Daeschlein G, Ahmed R, Pfeiffer S, Görlitz A, Simon D, Schön MP, Wandke D, Emmert S. Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm(®) VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622). J Eur Acad Dermatol Venereol. 2015 Jan;29(1):148-55. doi: 10.1111/jdv.12490. Epub 2014 Mar 25.</citation>
    <PMID>24666170</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cold atmospheric plasma</keyword>
  <keyword>pain</keyword>
  <keyword>bacteria</keyword>
  <keyword>skin parameters</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

